INS and type 2 diabetes mellitus: Despite the recent introduction of novel antidiabetic agents such as incretins and SGLT2 inhibitors and the more widespread use of bariatric surgery insulin therapy is ultimately required to maintain glycemic targets in a large proportion of severely obese patients with type 2 diabetes.